A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification

ᅟ: The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an effective, biomarker-guided treatment for metastatic colorectal cancer (mCRC) patients who are refractory to treatment with oxaliplatin-based chemotherapy and have TOP2A gene amplif...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Tarpgaard, Line S., Qvortrup, Camilla, Nygård, Sune B., Nielsen, Signe L., Andersen, Diana R., Jensen, Niels Frank, Stenvang, Jan, Detlefsen, Sönke, Brünner, Nils, Pfeiffer, Per
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4750171/
https://ncbi.nlm.nih.gov/pubmed/26867764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2124-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars